JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

Inicio・Lista de Acciones・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Cerrado

SectorSalud

8.89 2.42

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.67

Máximo

8.94

Métricas clave
By Trading Economics
Ingresos	-2.7M -24M
Ventas	29M 155M
Margen de beneficio	-15.787
Empleados	499
EBITDA	-1M -5.8M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+82.93% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	461M 2.3B
Apertura anterior	6.47
Cierre anterior	8.89

Noticias sobre sentimiento de mercado

By Acuity

48%

52%

145 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.925 / 7.38 Soporte y Resistencia

Amicus Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

26 oct 2025, 23:52 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 oct 2025, 23:52 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

26 oct 2025, 23:46 UTC

Charlas de Mercado

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 oct 2025, 23:41 UTC

Charlas de Mercado

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 oct 2025, 23:34 UTC

Ganancias

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 oct 2025, 23:32 UTC

Ganancias

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 oct 2025, 23:30 UTC

Ganancias

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 oct 2025, 22:29 UTC

Ganancias

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 oct 2025, 22:29 UTC

Ganancias

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 oct 2025, 22:29 UTC

Ganancias

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 oct 2025, 22:29 UTC

Ganancias

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 oct 2025, 22:16 UTC

Ganancias

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 oct 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 oct 2025, 19:29 UTC

Adquisiciones, fusiones, absorciones

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 oct 2025, 06:39 UTC

Ganancias

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 oct 2025, 06:39 UTC

Ganancias

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 oct 2025, 06:39 UTC

Ganancias

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 oct 2025, 21:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 oct 2025, 21:24 UTC

Charlas de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct 2025, 21:07 UTC

Ganancias

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct 2025, 20:58 UTC

Ganancias

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 oct 2025, 20:40 UTC

Ganancias

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct 2025, 20:24 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:23 UTC

Ganancias

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct 2025, 20:13 UTC

Ganancias

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct 2025, 20:07 UTC

Charlas de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct 2025, 19:40 UTC

Charlas de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct 2025, 19:35 UTC

Charlas de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct 2025, 19:33 UTC

Ganancias

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Comparación entre iguales

Cambio de precio

Amicus Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

82.93% repunte

Estimación a 12 meses

Media 15.86 USD 82.93%

Máximo 20 USD

Mínimo 12 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.925 / 7.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

145 / 373 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.